Ocugen Inc (OCGN)
$1.66
0.00 (0.00%)
OCGN Stock Quote Delayed 30 Minutes
7 Meme Stocks to Sell Before They Lose Momentum
Meme stocks run the gamut from senseless to sensible. These seven unfortunately fall in the former camp, so steer clear.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
427.16M
PE Ratio
-6.92
EPS
-0.24
Volume (Avg. Vol.)
24,980
Day's Range
-
52-Week Range
$0.35 - $2.11
Dividend & Yield
N/A (N/A)
OCGN Stock Predictions, Articles, and Ocugen Inc News
Investor Fears About Covaxin Have Ocugen Shares on Sale
OCGN stock at this point is either an inexpensive Covid-19 vaccine stock, or an over-priced investigational gene therapy stock — or both.
OCGN Stock Pops on Key FDA News. Here’s What to Know.
Ocugen is slipping today even after promising news breaks related to its gene therapy program, OCU400. Where is OCGN stock heading?
Ocugen Investors Are Betting On a Horse Than Can’t Win the Race
OCGN stock has declined to a level where a bounce is certainly possible, but not likely as Ocugen fails to demonstrate any profitability.
Ocugen Looks Risky as Markets Tire Of Speculative Vaccine Plays
The window of opportunity is closing for also-ran vaccine makers, which is why OCGN has become a very volatile stock in the vaccine space.
Ocugen Stock Very Well May Have Bottomed Out Here
I don’t know if InvestorPlace’s Larry Ramer is still short. But if he is, he’s made a few bucks with OCGN stock down 23% in the past month.
OCGN Stock Alert: The FDA News Sending Ocugen Plummeting Today
Shares of OCGN stock are under pressure after the FDA halted the approval process of Covaxin, a major setback for Ocugen.
Think Twice Before You Roll the Dice on Ocugen Stock
OCGN stock may spike once again on positive news, but investors' best best is to steer clear of it at this point in time.
The Slide in Ocugen Could Be a Slide to a Homerun
Ocugen has potential for its gene therapy treatment for eye diseases, but OCGN stock movement has been all about Covaxin.
Ocugen Proves Groupthink Is a Double-Edged Sword
While OCGN stock is an intriguing idea on the science, when the masses have a different framework, it becomes a risky proposition.
Ocugen Needs More Than Covaxin to Boost Its Falling Shares
A doomed-looking vaccine partnership puts Ocugen back in the business of obscurity and OCGN stock at risk of much lower prices.
As OCGN Stock Trudges Along Without Real Hope Must Wane
OCGN stock doesn't deserve the investment it receives and doesn't have much gas left in the tank at this point.
WHO’s Nod Can’t Mask Ocugen’s Flimsy Fundamentals
Ocugen has been trying to commercialize a Covid-19 vaccine. However, many obstacles remain. Meanwhile, insiders are dumping OCGN stock.
OCGN Stock Alert: The Earnings News That Has Ocugen Slipping Today
OCGN stock is pulling back after a muted earnings report this morning, as Ocugen makes a big bet on Covaxin for kids.
Sell-the-News Moment Is Your Chance to Reload on Ocugen
As Ocugen - or at least, a partner in developing a Covid-19 vaccine - receives a critical approval, OCGN stock could rebound soon.
Ocugen Stock Looks Poised to Take a Tumble Right Here
After WHO granted Covaxin a limited Emergency Use Listing, many institutions and hedge funds are likely to sell or short OCGN stock.
With Ocugen Stock: Follow The Lead of Traders and ‘Sell The News’
With its chances of experiencing another sharp slide in price likely. If you own OCGN stock today, cash out ASAP to avoid holding the bag. If you don't own it? Avoid at all costs.
Avoid Ocugen — The Vaccine Is Too Little, Too Late
With high percentage of vaccination in U.S. and Canada, Ocugen has a limited addressable market. With the company still waiting for official FDA approval for the Covaxin, it's advisable for investors to stay away.
Ocugen Neared $16 Yesterday, But I’ll Eat 4 Hats If It Gets to $32
OCGN stock has moved higher despite little evidence anything’s changed regarding Ocugen’s revenue potential in the U.S.
